Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.

Klupsch K, Baeriswyl V, Scholz R, Dannenberg J, Santimaria R, Senn D, Kage E, Zumsteg A, Attinger-Toller I, von der Bey U, K├Ânig-Friedrich S, Dupuy F, Lembke W, Albani C, Wendelspiess S, Dinkel L, Saro D, Hepler RW, Laszlo GS, Gudgeon CJ, Bertschinger J, Brack S, Walter RB.

Leukemia. 2019 Mar;33(3):805-808. doi: 10.1038/s41375-018-0249-z. Epub 2018 Sep 11. No abstract available.

PMID:
30206306
2.

A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action.

Brack S, Attinger-Toller I, Schade B, Mourlane F, Klupsch K, Woods R, Hachemi H, von der Bey U, Koenig-Friedrich S, Bertschinger J, Grabulovski D.

Mol Cancer Ther. 2014 Aug;13(8):2030-9. doi: 10.1158/1535-7163.MCT-14-0046-T. Epub 2014 Jul 3.

3.

Enhanced HtrA2/Omi expression in oxidative injury to retinal pigment epithelial cells and murine models of neurodegeneration.

Ding X, Patel M, Shen D, Herzlich AA, Cao X, Villasmil R, Klupsch K, Tuo J, Downward J, Chan CC.

Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4957-66. doi: 10.1167/iovs.09-3381. Epub 2009 May 14.

4.

Omi is a mammalian heat-shock protein that selectively binds and detoxifies oligomeric amyloid-beta.

Liu ML, Liu MJ, Shen YF, Ryu H, Kim HJ, Klupsch K, Downward J, Hong ST.

J Cell Sci. 2009 Jun 1;122(Pt 11):1917-26. doi: 10.1242/jcs.042226. Epub 2009 May 12.

5.

PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death.

Gandhi S, Wood-Kaczmar A, Yao Z, Plun-Favreau H, Deas E, Klupsch K, Downward J, Latchman DS, Tabrizi SJ, Wood NW, Duchen MR, Abramov AY.

Mol Cell. 2009 Mar 13;33(5):627-38. doi: 10.1016/j.molcel.2009.02.013.

6.

Mitochondrial dysfunction triggered by loss of HtrA2 results in the activation of a brain-specific transcriptional stress response.

Moisoi N, Klupsch K, Fedele V, East P, Sharma S, Renton A, Plun-Favreau H, Edwards RE, Teismann P, Esposti MD, Morrison AD, Wood NW, Downward J, Martins LM.

Cell Death Differ. 2009 Mar;16(3):449-64. doi: 10.1038/cdd.2008.166. Epub 2008 Nov 21.

7.

PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons.

Wood-Kaczmar A, Gandhi S, Yao Z, Abramov AY, Miljan EA, Keen G, Stanyer L, Hargreaves I, Klupsch K, Deas E, Downward J, Mansfield L, Jat P, Taylor J, Heales S, Duchen MR, Latchman D, Tabrizi SJ, Wood NW.

PLoS One. 2008 Jun 18;3(6):e2455. doi: 10.1371/journal.pone.0002455. Erratum in: PLoS ONE. 2008;3(7). doi: 10.1371/annotation/17d5aaa1-c6d8-4aad-a9a4-56b2c1220c83. Abramov, Andrey S Y [corrected to Abramov, Andrey Y]. PLoS ONE. 2008;3(7). doi: 10.1371/annotation/ba489c2a-5cf2-481c-aff7-d2c8c4ecdcfa.

8.

The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.

Plun-Favreau H, Klupsch K, Moisoi N, Gandhi S, Kjaer S, Frith D, Harvey K, Deas E, Harvey RJ, McDonald N, Wood NW, Martins LM, Downward J.

Nat Cell Biol. 2007 Nov;9(11):1243-52. Epub 2007 Sep 30.

PMID:
17906618
9.

The protease inhibitor Ucf-101 induces cellular responses independently of its known target, HtrA2/Omi.

Klupsch K, Downward J.

Cell Death Differ. 2006 Dec;13(12):2157-9. Epub 2006 May 12. No abstract available.

10.

Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication.

O'Shea C, Klupsch K, Choi S, Bagus B, Soria C, Shen J, McCormick F, Stokoe D.

EMBO J. 2005 Mar 23;24(6):1211-21. Epub 2005 Mar 3.

11.

Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice.

Martins LM, Morrison A, Klupsch K, Fedele V, Moisoi N, Teismann P, Abuin A, Grau E, Geppert M, Livi GP, Creasy CL, Martin A, Hargreaves I, Heales SJ, Okada H, Brandner S, Schulz JB, Mak T, Downward J.

Mol Cell Biol. 2004 Nov;24(22):9848-62.

Supplemental Content

Loading ...
Support Center